Creating a new class of gene therapies by targeting disease-causing messenger RNA
Employees: 11-50
Total raised: $155M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Vida Ventu... | vidaventur... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | UCB Ventur... | ucbventure... |
| - | RA Capital... | racap.com |
| - | Lightstone... | lightstone... |
| - | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.01.2021 | Series B | $100M | - |
| 23.05.2019 | Series A | $55M | - |
Mentions in press and media 17
| Date | Title | Description |
| 03.01.2021 | Locanabio Raises $100 Million in Series B Financing | Photo courtesy of Locanabio. Locanabio will pursue gene therapy treatments for severe neurodegenerative and neuromuscular diseases. San Diego-based Locanabio, a private preclinical-stage biotech company, has raised a $100 million Series B f... |
| 15.12.2020 | Daily funding roundup - Dec. 15th, 2020 | Modern Health raised $51M; Noname Security landed $25M; Iris Automation secured $13M Tive: Tive is a Boston-based company focused on providing more visibility into shipment tracking, including location data and condition insights like tempe... |
| 14.12.2020 | Locanabio Raises $100M in Series B Financing | Locanabio, Inc., a San Diego, CA-based RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, raised $100m in Series B financing. The round was led ... |
| 14.12.2020 | Locanabio Finds $100M For Gene Therapy | San Diego-based Locanabio, a biotech startup developing gene therapy to treat neurodegenerative, neuromuscular, and retinal diseases, has raised $100M in a Series B funding, the company said this morning. The funding was led by Vida Venture... |
| 14.12.2020 | Locanabio Announces $100M Series B Financing | SAN DIEGO, CA, has raised a $100 million Series B financing led by Vida .Ventures >> Click here for more funding data on Locana >> To export Locana funding data to PDF and Excel, click here Locanabio, an RNA-targeting gen... |
| 14.12.2020 | Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNATargeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases | 14 Dec 2020. Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced a $100 million Series B financ... |
| 14.12.2020 | LocanaBio has announced a $100M Series B financing to accelerate multiple programs into IND-enabling studies and further develop a novel RNA-targeting platform | - |
| 14.12.2020 | Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases | - |
| 14.12.2020 | San Diego’s Locanabio raises $100 million for treatments aimed at degenerative diseases | Locanabio, a San Diego gene therapy company focused on treatments for severe neurodegenerative diseases such as Huntington’s and Lou Gehrig’s disease, has raised $100 million in a second round of venture capital funding. The Torrey Pines Me... |
| 23.05.2019 | Temasek backs $55m Series A for US-based RNA gene therapy startup Locana | Premium Locana, a California-based RNA-targeting gene therapy startup, has raised $55 million in its Series A funding round backed by existing investor Temasek Holdings, Singapore’s state-owned investment firm, according to an announcement.... |
Show more